The relationship between the levels of gonadotropic hormones and OPG, leptin, TGF-β1 and TGF-β2 in Chinese adult women

Clinica Chimica Acta

Volumn 411, Issue 17-18, 2010, Pages 1296-1305

  Wu, Xi Yu ^a   Wu, Xian Ping ^a   Luo, Xiang Hang ^a   Xie, Hui ^a   Zhang, Hong ^a   Peng, Yi Qun ^a   Yuan, Ling Qing ^a   Jiang, Ye Bin ^b   Liao, Er Yuan ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

FSH; Leptin; LH; Osteoprotegerin; TGF 1; TGF 2

Indexed keywords

ESTRADIOL; FOLLITROPIN; GONADOTROPIN; LEPTIN; LUTEINIZING HORMONE; OSTEOPROTEGERIN; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

ADULT; AGED; ARTICLE; BODY MASS; CHINESE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; OSTEOBLAST; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN INTERACTION; WOMEN'S HEALTH; BLOOD; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; LEPTIN; LUTEINIZING HORMONE; MIDDLE AGED; OSTEOPROTEGERIN; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

EID: 77954141869     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.05.006     Document Type: Article

References (58)

1. Hall J.E. Neuroendocrine changes with reproductive aging in women. Semin Reprod Med 2007, 25:344-351.
2. Baron R. FSH versus estrogen: who's guilty of breaking bones?. Cell Metab 2006, 3:302-305.
3. Sendak R.A., Sampath T.K., McPherson J.M. Newly reported roles of thyroid-stimulating hormone and follicle-stimulating hormone in bone remodeling. Int Orthop 2007, 31:753-757.
4. Mansell J.P., Bailey A.J., Yarram S.J. Could bone tissue be a target for luteinizing hormone/chorionic gonadotropin?. Mol Cell Endocrinol 2007, 169:99-106.
5. Ausmanas M.K., Tan D.A., Jaisamrarn U., Tian X.W., Holinka C.F. Estradiol, FSH and LH profiles in nine ethnic groups of postmenopausal Asian women: the Pan-Asia Menopause (PAM) study. Climacteric 2007, 10:427-437.
6. Riggs B.L., Khosla S., Melton L.J. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002, 23:279-302.
7. Prior J.C. FSH and bone-important physiology or not?. Trends Mol Med 2006, 13:1-3.
8. Seibel M.J., Dunstan C.R., Zhou H., Allan C.M., Handelsman D.J. Sex steroids, not FSH, influence bone mass. Cell 2006, 127:1079.
9. Sun L., Peng Y., Sharrow A.C., et al. FSH directly regulates bone mass. Cell 2006, 125:247-260.
10. Devleta B., Adem B., Senada S. Hypergonadotropic amenorrhea and bone density: new approach to and old problem. J Bone Miner Metab 2004, 22:360-364.
11. Yu Q., Lin S., He F., et al. Clinical manifestations of low bone mass in amenorrhea patients with increased follicular stimulating hormone. Chin Med J 2002, 115:1376-1379.
12. Desai Meena P., Khatkhatay M.I., Bhanu Prakash K.V., Savardekar L.S., Shah R.S., Ansari Z. Hormonal profiles and biochemical indices of bone turnover in Indian women. Osteoporos Int 2007, 18:923-929.
13. Xu Z.R., Wang A.H., Wu X.P., et al. Relationship of age-related concentrations of serum FSH and LH with bone mineral density, prevalence of osteoporosis in native Chinese women. Clin Chim Acta 2009, 400:8-13.
14. Zhao G., Wang L., Yan R., Dennerstein L. Menopausal symptoms: experience of Chinese women. Climacteric 2002, 3:135-144.
15. Janssens K., ten Dijke P., Janssens S., Van Hul W. Transforming growth factor-beta 1 to the bone. Endocr Rev 2005, 26:743-774.
16. Simonet W.S., Lacey D.L., Dunstan C.R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
17. Elefteriou F., Takeda S., Ebihara K., et al. Serum leptin level is a regulator of bone mass. Proc Natl Acad Sci U S A 2004, 101:3258-3263.
18. Fuller K., Lean J.M., Bayley K.E., Wani M.R., Chambers T.J. A role for TGF-β1 in osteoclast differentiation and survival. J Cell Sci 2000, 113:2445-2453.
19. Chenu C., Pfeilschifter J., Mundy G.R., Roodman G.D. Transforming growth factor beta inhibits formation of osteoclast-like cells in long-term human marrow cultures. Proc Natl Acad Sci U S A 1988, 85:5683-5687.
20. Hofbauer L.C., Khosla S., Dunstan C.R., Lacey D., Boyle W.J., Riggs B.L. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000, 15:2-12.
21. Mizuno A., Amizuka N., Irie K., et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998, 247:610-615.
22. Yasuda H., Shima N., Nakagawa N., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998, 95:3597-3602.
23. Mezquita-Raya P., de la Higuera M., García D.F., et al. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. Osteoporos Int 2005, 16:1368-1374.
24. Rogers A., Saleh G., Hannon R.A., Greenfield D., Eastell R. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab 2002, 87:4470-4475.
25. Thomas T. Leptin and fragility fracture: evidence for a protective effect in humans. Am J Med 2004, 117:966-968.
26. Ducy P., Amling M., Takeda S., et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000, 100:197-207.
27. Fu L., Patel M.S., Bradley A., Wagner E.F., Karsenty G. The molecular clock mediates leptin-regulated bone formation. Cell 2005, 122:803-815.
28. Elefteriou F., Ahn J.D., Takeda S., et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 2005, 434:514-520.
29. Pasco J.A., Henry M.J., Kotowicz M.A., et al. Serum leptin levels are associated with bone mass in nonobese women. J Clin Endocrinol Metab 2001, 86:1884-1887.
30. Yamauchi M., Sugimoto T., Yamaguchi T., et al. Plasma leptin concentrations are associated with bone mineral density and the presence of vertebral fractures in postmenopausal women. Clin Endocrinol 2001, 55:341-347.
31. Blain H., Vuillemin A., Guillemin F., et al. Serum leptin level is a predictor of bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2002, 87:1030-1035.
32. Weiss L.A., Barrett-Connor E., von Mühlen D., Clark P. Leptin predicts BMD and bone resorption in older women but not older men: the Rancho Bernardo Study. J Bone Miner Res 2006, 21:758-764.
33. Wu X.Y., Wu X.P., Xie H., et al. Relationship between age-related reference values of serum osteoprotegerin and leptin in native Chinese women and compared with those in women of other races. Clin Chim Acta 2008, 389:72-78.
34. Prevot V., Bouret S., Croix D., et al. Evidence that members of the TGFbeta superfamily play a role in regulation of the GnRH neuroendocrine axis: expression of a type I serine-threonine kinase receptor for TGRbeta and activin in GnRH neurones and hypothalamic areas of the female rat. J Neuroendocrinol 2000, 12:665-670.
35. Bouret S., De Seranno S., Beauvillain J.C., Prevot V. Transforming growth factor beta1 may directly influence gonadotropin-releasing hormone gene expression in the rat hypothalamus. Endocrinology 2004, 145:1794-1801.
36. Galbiati M., Saredi S., Romanò N., Martini L., Motta M., Melcangi R.C. Smad proteins are targets of transforming growth factor beta1 in immortalised gonadotrophin-releasing hormone releasing neurones. J Neuroendocrinol 2005, 17:753-760.
37. Melcangi R.C., Galbiati M., Messi E., Piva F., Martini L., Motta M. Type 1 astrocytes influence luteinizing hormone-releasing hormone release from the hypothalamic cell line GT1-1: is transforming growth factor-beta the principle involved?. Endocrinology 1995, 136:679-686.
38. Galbiati M., Zanisi M., Messi E., Cavarretta I., Martini L., Melcangi R.C. Transforming growth factor-beta and astrocytic conditioned medium influence luteinizing hormone-releasing hormone gene expression in the hypothalamic cell line GT1. Endocrinology 1996, 137:5605-5609.
39. Messi E., Galbiati M., Magnaghi V., Zucchi I., Martini L., Melcangi R.C. Transforming growth factor beta2 is able to modify mRNA levels and release of luteinizing hormone-releasing hormone in a immortalized hypothalamic cell line (GT1-1). Neurosci Lett 1999, 270:165-168.
40. Watanobe H. Leptin directly acts within the hypothalamus to stimulate gonadotropin-releasing hormone secretion in vivo in rats. J Physiol 2002, 545:255-268.
41. Yu W.H., Kimura M., Walczewska A., Karanth S., McCann S.M. Role of leptin in hypothalamic-pituitary function. Proc Natl Acad Sci U S A 1997, 94:1023-1028.
42. Chan J.L., Mantzoros C.S. Leptin and the hypothalamic-pituitary regulation of the gonadotropin-gonadal axis. Pituitary 2001, 4:87-92.
43. Iqbal J., Sun L., Kumar T.R., Blair H.C., Zaidi M. Follicle-stimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast formation. Proc Natl Acad Sci U S A 2006, 103:14925-14930.
44. Wu X.Y., Wu X.P., Xie H., et al. Age-related changes in biochemical markers of bone turnover and gonadotropin levels and their relationship among Chinese adult women. Osteoporos Int 2010, 21:275-285.
45. Thirunavukkarasu K., Miles R.R., Halladay D.L., et al. Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-β (TGF-β). J Biol Chem 2001, 276:36241-36250.
46. Karsdal M.A., Hjorth P., Henriksen K., et al. Transforming growth factor-β controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression. J Biol Chem 2003, 278:44975-44987.
47. Geiser A.G., Zeng Q.Q., Sato M., Helvering L.M., Hirano T., Turner C.H. Decreased bone mass and bone elasticity in mice lacking the transforming growth factor-beta 1 gene. Bone 1998, 23:87-93.
48. Karst M., Gorny G., Sells Galvin R.J., Oursler M.J. Roles of stromal cell RANKL, OPG, and M-CSF expression in biphasic TGF-β regulation of osteoclast differentiation. J Cell Physiol 2004, 200:99-106.
49. Toom A., Arend A., Gunnarsson D., et al. Bone formation zones in heterotopic ossification: histologic findings and increased expression of bone morphogenetic protein 2 and transforming growth factors β2 and β3. Calcif Tissue Int 2007, 80:259-267.
50. Martin A., de Vittoris R., David V., et al. Leptin modulates both resorption and formation while preventing disuse-induced bone loss in tail-suspended female rats. Endocrinology 2005, 146:3652-3659.
51. Holloway W.R., Collier F.M., Aitken C.J., et al. Leptin inhibits osteoclast generation. J Bone Miner Res 2002, 17:200-209.
52. Randolph J.F., Sowers M., Bondarenko I.V., Harlow S.D., Luborsky J.L., Little R.J. Change in estradiol and follicle-stimulating hormone across the early menopausal transition: effects of ethnicity and age. J Clin Endocrinol Metab 2004, 89:1555-1561.
53. Luetters C., Huang M.H., Seeman T., et al. Menopause transition stage and endogenous estradiol and follicle-stimulating hormone levels are not related to cognitive performance: cross-sectional results from the study of women's health across the nation (SWAN). J Womens Health 2007, 16:331-344.
54. Salmen T., Heikkinen A.M., Mahonen A., et al. Relation of aromatase gene polymorphism and hormone replacement therapy to serum estradiol levels, bone mineral density, and fracture risk in early postmenopausal women. Ann Med 2003, 35:282-288.
55. Riancho J.A., Zarrabeitia M.T., Valero C., et al. Aromatase gene and osteoporosis: relationship of ten polymorphic loci with bone mineral density. Bone 2005, 36:917-925.
56. Simpson E.R. Role of aromatase in sex steroid action. J Mol Endocrinol 2000, 25:149-156.
57. Oh E.S., Rhee E.J., Oh K.W., et al. Circulating osteoprotegerin levels are associated with age, waist-to-hip ratio, serum total cholesterol, and low-density lipoprotein cholesterol levels in healthy Korean women. Metabolism 2005, 54:49-54.
58. Oh K.W., Rhee E.J., Lee W.Y., et al. The relationship between circulating osteoprotegerin levels and bone mineral metabolism in healthy women. Clin Endocrinol 2004, 61:244-249.